Infliximab vs biosimilar: Withdrawals due to adverse events
- Population
- patients with Crohn's disease (with mixed/low disease activity at baseline)
- Intervention
- Infliximab
- Comparison
- biosimilar
- Outcome
- Withdrawals due to adverse events
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Infliximab vs biosimilar Withdrawal due to adverse events (at 52 weeks) · patients with Crohn's disease (with mixed/low disease activity at baseline) Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty). Infliximab for maintenance of medically‐induced remission in Crohn's disease (2024) · Cochrane Headline outcomes only | RR 20.73 [2.86, 150.33] | 1 study · 155 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Infliximab for maintenance of medically‐induced remission in Crohn's disease 2024 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Infliximab vs placebo · patients with Crohn's disease (mixed disease activity population with clinical response… · 1 review
- Infliximab vs purine analogues · Participants with Crohn's disease in remission · 1 review
- Infliximab vs adalimumab · patients with Crohn's disease (active disease population with clinical response at… · 1 review
- Infliximab vs rituximab · adults (age 18 years and older) with refractory GPA ANCA‐associated vasculitis · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.